Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease151

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease136

Views

Views
January 20251
February 20254
March 202517
April 20253
May 202571
June 202537
July 20253
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore122
United States11
Brazil2
Spain1
 

Top cities views

Views
Council Bluffs1
Ipiranga do Norte1
McAllen1
New York1
Pasadena1
Santa Cruz do Sul1
Seattle1
Spiro1